Form 8-K - Current report:
SEC Accession No. 0001753926-25-001353
Filing Date
2025-08-18
Accepted
2025-08-18 08:05:50
Documents
14
Period of Report
2025-08-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K g084926_8k.htm   iXBRL 8-K 43765
2 EXHIBIT 99.1 g084926_ex99-1.htm EX-99.1 31576
3 GRAPHIC image_002.jpg GRAPHIC 4008
  Complete submission text file 0001753926-25-001353.txt   257227

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE pths-20250818.xsd EX-101.SCH 3011
5 XBRL LABEL FILE pths-20250818_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE pths-20250818_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT g084926_8k_htm.xml XML 3896
Mailing Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703
Business Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 919-908-2422
Pelthos Therapeutics Inc. (Filer) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41964 | Film No.: 251226321
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)